Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
University of Miami
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05296070CT.gov Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | — | Recruiting | — | — | — |
NCT02669017CT.gov Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marginal Zone Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Loncastuximab Tesirine (this asset) | University of Miami | P2 | CCC · 55 |
| Etoposide | University of Miami | P2 | BBB |
| Orelabrutinib | Henan Cancer Hospital | P4 | BBB |
| Vincristine Sulfate | Mayo Clinic | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Nivestim | Fred Hutchinson Cancer Center | P2 | BBB |
| Rituximab | City of Hope Medical Center | P4 | BB |
| Fludarabine | Paolo Caimi, MD | P2 | BB |
| Romidepsin | City of Hope Medical Center | P2 | BB |
+42 more in the Marginal Zone Lymphoma cohort
Other indications for Loncastuximab Tesirine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Non-Hodgkin Lymphoma | — | P2/3 | B · 61 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P3 | CCC · 54 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Loncastuximab Tesirine in Marginal Zone Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/loncastuximab-tesirine-marginal-zone-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →